VitaliThyNCT07570316
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 8 versions: 8 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 32 → 35 locations
- Minor Trial sites expanded: 26 → 32 locations
- Minor Trial sites expanded: 23 → 26 locations
- Site details revised at 4 of 26 sites
- Minor Study sites: 23 to 26
- Notable Eligibility criteria expanded, about 9 words
- Study sites: 22 to 23
- Secondary endpoints: details revised at 4 of 20 entries
- Minor Trial sites expanded: 18 → 22 locationsv3
- Notable Recruitment opened
- Trial sites expanded: 0 → 18 locations
- Start date changed from estimate of Jun 2026 to Jun 10, 2026
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (20)
Show 15 moreShow less
Arms and interventions
Participants will receive efgartigimod PH20 SC Via Prefilled Syringe (PFS) during the part A double-blinded treatment period.
Participants will receive placebo PH20 SC Via Prefilled Syringe (PFS) during the part A double-blinded treatment period.
Participants will receive efgartigimod PH20 SC Via Prefilled Syringe (PFS) during the part B treatment period.
Participants will receive placebo PH20 SC Via Prefilled Syringe (PFS) during the part B treatment period.
Participants will receive efgartigimod PH20 SC PFS in the part C open-label treatment period
Biologicals: Efgartigimod PH20 SC
Other: Placebo PH20 SC
Sites
35 sites in 3 countries
United States 29, Georgia 5, United Kingdom 1